Clinical trial
TachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular…
NCT00440401 · Nycomed, Industry · Completed
Key facts
| NCT number | NCT00440401 |
|---|---|
| Title | TachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular Surgery (TC-023-IM) |
| Official title | A Randomised, Open Label, Parallel-group, Multi-centre Trial to Compare the Efficacy and Safety of TachoSil® Versus Standard Haemostatic Treatment in Cardiovascular Surgery |
| Lead sponsor | Nycomed, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Haemorrhage, Haemostasis, Cardiovascular Surgery |
| Intervention type | Drug |
| Interventions | fibrinogen (human) + thrombin (human), Standard haemostatic treatment in cardiovascular surgery |
| Enrollment | 120 |
| Start date | Feb 1, 2007 |
| Primary completion | Aug 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Feb 27, 2007 |
| Last update posted | May 8, 2012 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: